Page 261 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 261
P0810 SOFOSBUVIR AND DACLATASVIR COMBINED TREATMENT ePOSTERS
FOR CHRONIC HEPATITIS C : FIRST-YEAR EFFICACY AND
P0811 SAFETY DATA IN A REAL-LIFE SETTING
P0812 André-Jean Rémy*, Alexandre Pariente, Jean-Pierre Arpurt, Isabelle Rosa-
P0813 Hézode, Christophe Renou, Ramuntxo Arotcarena, Gilles Macaigne,
P0814 Hortensia Lison, François Bourhis, Xavier Causse, Arnaud Pauwels,
Stéphanie de Montigny-Lenhardt, Vincent Jouannaud, Hélène Labadie,
Eric Maringe, Jean-Hatem Salloum, Edmond Gagea, Hervé Hagège,
Bruno Lesgourgues, France
SOFOSBUVIR-BASED DIRECT-ACTING ANTIVIRALS
TREATMENT FOR ELDERLY CHRONIC HEPATITIS C
PATIENTS: A COST-EFFECTIVENESS ANALYSIS
Antonio Ciaccio*, Paolo A. Cortesi, Giuseppe Bellelli, Matteo Rota,
Monica Rota, Stefano Okolicsanyi, Lorenzo G. Mantovani,
Giorgio Annoni, Mario Strazzabosco, Italy
IMPACT OF SVRW12 IN THE DEVELOPMENT OF
COMPLICATIONS AND FIBROSIS REGRESSION IN
PATIENTS TREATED WITH TRIPLE THERAPY WITH
BOCEPREVIR AND TELAPREVIR
Christie Perelló*, Joaquin Cabezas, Elba Llop, Susana Menéndez,
Juan De La Revilla, Javier Crespo, José Luis Calleja, Spain
ALL ORAL THERAPY (SOFOSBUVIR-RIBAVIRIN)
COMBINATION IN SEVERE HCV-MIXED
CRYOGLOBULINEMIA VASCULITIS, THE VASCUVALDIC
STUDY
David Saadoun*, V Thibault, G Pialoux, L Elkrief, M Mallet, L Musset,
D Bazin Kara, C Cazorla, S Pol, Patrice Cacoub, France
HEPATIC IMPROVEMENT IN RESPONSE TO
LEDIPASVIR/SOFOSBUVIR/RIBAVIRIN AS MEASURED
BY THE HEPQUANT® (HQ)-SHUNT TEST IN LIVER
TRANSPLANT (LT) RECIPIENTS WITH ALLOGRAFT
FIBROSIS OR CIRRHOSIS AND NON-LT PATIENTS WITH
DECOMPENSATED CIRRHOSIS
James R. Burton*, Jacqueline G. O’Leary, Steve Helmke,
Andrea Herman, Michael Cookson, Shannon Lauriski, James F. Trotter,
Jill Denning, Phillip Pang, John McHutchison, Michael P. Curry,
Gregory T. Everson, The United States
Vienna, Austria • April 22–26, 2015 261
FOR CHRONIC HEPATITIS C : FIRST-YEAR EFFICACY AND
P0811 SAFETY DATA IN A REAL-LIFE SETTING
P0812 André-Jean Rémy*, Alexandre Pariente, Jean-Pierre Arpurt, Isabelle Rosa-
P0813 Hézode, Christophe Renou, Ramuntxo Arotcarena, Gilles Macaigne,
P0814 Hortensia Lison, François Bourhis, Xavier Causse, Arnaud Pauwels,
Stéphanie de Montigny-Lenhardt, Vincent Jouannaud, Hélène Labadie,
Eric Maringe, Jean-Hatem Salloum, Edmond Gagea, Hervé Hagège,
Bruno Lesgourgues, France
SOFOSBUVIR-BASED DIRECT-ACTING ANTIVIRALS
TREATMENT FOR ELDERLY CHRONIC HEPATITIS C
PATIENTS: A COST-EFFECTIVENESS ANALYSIS
Antonio Ciaccio*, Paolo A. Cortesi, Giuseppe Bellelli, Matteo Rota,
Monica Rota, Stefano Okolicsanyi, Lorenzo G. Mantovani,
Giorgio Annoni, Mario Strazzabosco, Italy
IMPACT OF SVRW12 IN THE DEVELOPMENT OF
COMPLICATIONS AND FIBROSIS REGRESSION IN
PATIENTS TREATED WITH TRIPLE THERAPY WITH
BOCEPREVIR AND TELAPREVIR
Christie Perelló*, Joaquin Cabezas, Elba Llop, Susana Menéndez,
Juan De La Revilla, Javier Crespo, José Luis Calleja, Spain
ALL ORAL THERAPY (SOFOSBUVIR-RIBAVIRIN)
COMBINATION IN SEVERE HCV-MIXED
CRYOGLOBULINEMIA VASCULITIS, THE VASCUVALDIC
STUDY
David Saadoun*, V Thibault, G Pialoux, L Elkrief, M Mallet, L Musset,
D Bazin Kara, C Cazorla, S Pol, Patrice Cacoub, France
HEPATIC IMPROVEMENT IN RESPONSE TO
LEDIPASVIR/SOFOSBUVIR/RIBAVIRIN AS MEASURED
BY THE HEPQUANT® (HQ)-SHUNT TEST IN LIVER
TRANSPLANT (LT) RECIPIENTS WITH ALLOGRAFT
FIBROSIS OR CIRRHOSIS AND NON-LT PATIENTS WITH
DECOMPENSATED CIRRHOSIS
James R. Burton*, Jacqueline G. O’Leary, Steve Helmke,
Andrea Herman, Michael Cookson, Shannon Lauriski, James F. Trotter,
Jill Denning, Phillip Pang, John McHutchison, Michael P. Curry,
Gregory T. Everson, The United States
Vienna, Austria • April 22–26, 2015 261
